Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression.
|
29377616 |
2018 |
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A lower progression to cirrhosis was found in NASVAC group compared to Peg-IFN group.
|
30133478 |
2018 |
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a result of the exceedingly high cost of DAAs in many countries, IFN-free DAA regimens are mostly reserved to patients with advanced fibrosis or cirrhosis.
|
26725891 |
2016 |
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These patients received 4 weeks of PEG-IFN/RBV (lead-in), followed by response-guided therapy with PEG-IFN/RBV plus BOC (a fixed 44 weeks was indicated in the case of cirrhosis).
|
27815225 |
2016 |
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The recent October 2014 approval of the fixed dose combination (FDC) of the NS5B polymerase inhibitor sofosbuvir (SOF) and the NS5A inhibitor ledipasvir (LDV) for the treatment of treatment-naive and -experienced HCV genotype 1a/1b (HCV-1) has marked a new era of IFN and ribavirin free treatment for chronic hepatitis C. SOF/LDV combination is approved for 12 weeks in treatment-naive patients with and without cirrhosis.
|
25676581 |
2015 |
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results are as follows: (1) both ETV and TDF showed long-term efficacy and safety; (2) PEG IFN-α resulted in a greater decline in HBV DNA levels and a higher rate of HBeAg seroconversion; (3) combination therapy with IFN plus two analogues did not elevate the rate of sustained responses; (4) both ETV and TDF showed efficacy and safety with cirrhosis (ETV especially displayed efficacy and safety with decompensated cirrhosis), and (5) suppression of HCC was observed by ETV and IFN.
|
26584037 |
2015 |
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In patients with HCV genotype 1 (HCV-1), a PEG-IFN/RBV-based regimen with sofosbuvir is highly effective but the presence of cirrhosis and the non-CC IFNL3 genotype have been associated with a poorer response.
|
25529083 |
2015 |
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results of the first oral combination of Sofosbuvir and RBV for 12 weeks in genotype 3-infected patients have been rather disappointing with a slightly lower SVR than after 24 weeks of PEG-IFN: around 60%, and only 30% in patients with cirrhosis.
|
24373074 |
2014 |
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The efficacy of peg-IFN plus RBV among HIV/HCV-coinfected patients with cirrhosis is lower than in those without cirrhosis, although this antiviral combination still leads to a substantial rate of SVR in those carrying HCV genotype 3.
|
22955435 |
2012 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Power and sample size were a priori calculated and 96 consecutive chronic hepatitis C patients (53, genotype 2 and 43, genotype 3) without cirrhosis who were not obese and who achieved a RVR to therapy with peg-IFN-α-2a and ribavirin were enrolled.
|
22497814 |
2012 |
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Full-dose antiviral therapy with PEG-IFN and ribavirin can be safely carried out even in patients with compensated, fully established cirrhosis and portal hypertension.
|
19849774 |
2009 |
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to assess whether cirrhosis modifies the pattern of PEG-IFN-alpha2b and RBV treatment failure.
|
19578243 |
2009 |
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because PEG-IFN therapy results in a high rate of sustained off-therapy response, patients with advanced fibrosis or cirrhosis but compensated liver disease should not be excluded from PEG-IFN treatment.
|
17604363 |
2007 |
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Peg-IFN therapy seems to slow down the rate of cirrhosis progression also in HIV/HCV co-infected patients nonresponders to anti-HCV therapy, in comparison with untreated patients.
|
17802905 |
2007 |
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IFN therapy reduces cirrhosis and HCC development.
|
17107734 |
2007 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Productive infections have been achieved recently with genotype 2a virus, but cirrhosis and liver cancer are typically associated with genotype 1 HCV, which is more prevalent and relatively resistant to IFN therapy.
|
16461899 |
2006 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
During follow-up, two patients of the control group and three patients of the IFN group developed cirrhosis, and one of the IFN- treated patients progressed to hepatocellular carcinoma.
|
16012762 |
2005 |
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
HCV genotype 2a/c, absence of cirrhosis and a low cryocrit (<9%) were predictive factors of high response rate to IFN.
|
9431896 |
1997 |
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In a pilot study of long-term treatment, 42 such patients were randomly assigned to 6 million units of interferon alfa 2b (IFN-alpha2b) three times per week for 24 consecutive months (n = 21, 4 with cirrhosis) or to no therapy (n = 21, 3 with cirrhosis).
|
9398007 |
1997 |